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Abstract
Background: Pretargeted imaging allows the use of short-lived radionuclides when imaging the accumulation of
slow clearing targeting agents such as antibodies. The biotin-(strept)avidin and the bispecific antibody-hapten
interactions have been applied in clinical pretargeting studies; unfortunately, these systems led to immunogenic
responses in patients. The inverse electron demand Diels-Alder (IEDDA) reaction between a radiolabelled tetrazine
(Tz) and a trans-cyclooctene (TCO)-functionalized targeting vector is a promising alternative for clinical pretargeted
imaging due to its fast reaction kinetics. This strategy was first applied in nuclear medicine using an 111In-labelled
Tz to image TCO-functionalized antibodies in tumour-bearing mice. Since then, the IEDDA has been used extensively
in pretargeted nuclear imaging and radiotherapy; however, these studies have only been performed in mice. Herein,
we report the 44Sc labelling of a Tz and evaluate it in pretargeted imaging in Wistar rats.
Results: 44Sc was obtained from an in house 44Ti/44Sc generator. A 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA)-functionalized tetrazine was radiolabelled with 44Sc resulting in radiochemical yields of 85–95%, a
radiochemical purity > 99% at an apparent molar activity of 1 GBq/mmol. The 44Sc-labelled Tz maintained
stability in solution for up to 24 h. A TCO-functionalized bisphosphonate, which accumulates in skeletal tissue,
was used as a targeting vector to evaluate the 44Sc-labelled Tz. Biodistribution data of the 44Sc-labelled Tz
showed specific uptake (0.9 ± 0.3% ID/g) in the bones (humerus and femur) of rats pre-treated with the TCO-
functionalized bisphosphonate. This uptake was not present in rats not receiving pre-treatment (< 0.03% ID/g).
Conclusions: We have prepared a 44Sc-labelled Tz and used it in pretargeted PET imaging with rats treated
with TCO-functionalized bisphosponates. This allowed for the evaluation of the IEDDA reaction in animals
larger than a typical mouse. Non-target accumulation was low, and there was a 30-fold higher bone uptake
in the pre-treated rats compared to the non-treated controls. Given its convenient half-life and the ability to
perform positron emission tomography with a previously studied DOTA-functionalized Tz, scandium-44 (t1/2 =
3.97 h) proved to be a suitable radioisotope for this study.
Keywords: Scandium-44 (44Sc), Positron emission tomography (PET), Tetrazine, Trans-cyclooctene (TCO),
Pretargeted imaging, Inverse electron demand Diels-Alder (IEDDA), Bisphosphonates, Alendronic acid
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Background
Personalized medicine (precision medicine) is a practice
where the patient’s individual biological/molecular charac-
teristics are used to determine a course of treatment [1].
Although this concept can be traced back to Hippocrates
[1], advancements in chemical biology, molecular biology,
systems biology, and genomics have inspired resurgence
in its practice. Nuclear medicine techniques such as single
photon computed tomography (SPECT) and positron
emission tomography (PET) play an important role
through the use of companion diagnostics in innovative
theranostic approaches [2]. Companion diagnostics are
agents that can be used to identify a biomarker indicative
of a particular disease phenotype. From this information,
predictions regarding how a patient may respond to a par-
ticular course of treatment can be derived [3]. Unlike
other diagnostic tests, radiotracers can be used repeatedly
and reflect a particular biologic property throughout the
whole body giving a complete view of the disease. This is
particularly useful in the case of systemically applied tar-
geted radiotherapy. In this instance, the companion diag-
nostics (or theranostic) agent is used as a surrogate for the
radiotherapeutic. For example, it can be used to evaluate
pretherapeutic dosimetry, biodistribution, and maximal
tolerated dose prior to administering the radiotherapeutic.
The theranostic approach has been an important factor
in the recent developments in radioimmunotherapy mainly
due to pretherapeutic dosimetry and measuring treatment
response [4]. One of the main drawbacks in radioimmu-
notherapy though is the sub-optimal pharmacokinetic
properties of the antibodies. Due to their long circulation
time and slow target accumulation, the radiation burden to
the patient can be quite high. This necessitates the use of
long-lived radioisotopes further increasing the radiation
dose. This can be mitigated with a pretargeting strategy.
With this method, there is a temporal separation of the tar-
geting step from the delivery of the radiation at the target
site. The process involves a primary agent and a secondary
agent, each functionalized with tags that specifically bind to
each other in a biological medium. This method can be
applied using bioorthogonal chemical reactions such as the
inverse electron demand Diels-Alder (IEDDA) reaction,
namely the trans-cyclooctene (TCO)-tetrazine (Tz) ligation.
The first application of this method in nuclear medicine in-
volved a tetrazine labelled with indium-111 via the 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
chelator (1) [5]. Following this success, a number of Tz
have been developed for diagnostic purposes [6–9], but also
a few DOTA-Tz have been labelled with therapeutic
isotopes such as lutetium-177 and lead-212 with the hope
of providing pretargeted radioimmunotherapy [10–12].
Although any modality can be used to predict the efficacy
of a radiotherapeutic, PET is most advantageous due to the
level of quantification aiding in more accurate dosimetry
measurements. Traditionally, a theranostic in nuclear medi-
cine is an agent consisting of a dual-purpose radionuclide
that can be used in both diagnostic and therapeutic applica-
tions. However, often times, a radionuclide pair, consisting of
either isotopes of the same element or two chemical
congeners, can be used as well [13].
For example, scandium-44 is an attractive PET radio-
nuclide for this purpose due to its half-life and emission
properties. The half-life for scandium-44 (3.97 h) is
long enough for production and transport, yet short
enough that radiation doses are minimized.
Scandium-44 has a high positron branching ratio
(β+branch = 94.27%) and a suitable positron energy
(Eβ,max = 1.474) resulting in high image quality for
44Sc-labelled radiopharmaceuticals [14, 15]. Further-
more, scandium and lutetium have similar coordination
chemistry and the stability of Sc-DOTA complexes is
higher than both 177Lu-DOTA and the often used 68Ga-
DOTA [16, 17] [14, 18]. Scandium-44 can be produced
from a cyclotron as well as a 44Ti/44Sc generator. Fol-
lowing these innovations, there has been increased
interest in using scandium-44 as a PET alternative to
gallium-68 for clinical and preclinical applications [16–
19].
The aim of the current study was to develop a 44Sc-la-
belled variant of 1 and evaluate its use for pretargeted PET
imaging. The primary agent was a TCO-functionalized vari-
ant of the bisphosphonate, alendronic acid (Aln-TCO, 2)
(Fig. 1). Alendronic acid is used in the clinic to treat osteo-
porosis, and it accumulates in areas with high bone turnover
[20]. TCO-modified alendronic acid has been used to screen
radiolabelled tetrazines for in vivo pretargeting in healthy
mice [21–23] [20, 24, 25]. The possibility to screen in healthy
animals is advantageous for applications in higher order spe-
cies because a disease model is not needed. Furthermore,
TCO-modified alendronic acid accumulates at their target
sites quickly and exhibits fast clearance from non-targeted
tissues. Consequently, clearing agents or lengthy pretargeting
lag times are not required as in the case with
TCO-functionalized antibodies [21]. One of the challenges in
using bioorthogonal reactions for pretargeted imaging is that
the reaction kinetics are concentration dependent. This can
alter the effectiveness of the reaction when moving from
smaller living species to larger ones. For example, early stud-
ies applying the Staudinger ligation in vivo were successful in
cells, yet the system failed once it was applied to mice
models [26–28]. To date, pretargeted imaging using the
TCO-Tz ligation has only been reported in mice (ca. 20 g).
Various radiolabelled bisphosphonates have been evaluated
in healthy Wistar rats as potential agents to image bone me-
tastasis leading to clinical evaluation in patients with skeletal
metastases [22, 23, 29, 30]. Therefore, the current pretar-
geted imaging studies were performed using the larger Wis-
tar rats (ca. 150+ g).
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Methods
General
All reagents and solvents were purchased from Sigma-Al-
drich, unless otherwise stated, and used without further
purification. Aln-TCO (2) [24] and the
DOTA-functionalized tetrazine (1) were prepared as previ-
ously described [5]. [44Sc]ScCl3 (120–130MBq) was ob-
tained from an in house 44Ti/44Sc generator in 0.25M
sodium acetate pH 4 (3mL) as described previously [31].
TraceSELECT water (Honeywell) was used for the radiola-
belling reactions. Analytical radioactive thin-layer chroma-
tography (radio-TLC) was performed using silica gel plates
or C18 plates (Merk) with fluorescent indicator UV254 and
visualized using a RITA TLC imager (Elysia Raytest). Ana-
lytical high-performance liquid chromatography (HPLC)
was performed using a Sykam S 1100 solvent delivery sys-
tem, S 8110 system equipped with a Dionex UVD 170U
(254 nm) absorbance detector and a Raytest NaI scintilla-
tion counter (Gabi) radioactivity detector. Compounds
were eluted using a Chromalith Performance RP-18 end-
capped 100-4.6 HPLC column using the following elution
conditions: solvent A =water with 0.1% trifluoroacetic acid
(TFA), solvent B = acetonitrile with 0.1% TFA; gradient 5%
B to 95% B, 0–10min. The flow rate was set at 2.5mL/min.
UV monitoring occurred at 254 nm.
44Sc labelling
To a vial containing [44Sc]ScCl3 in 0.25M NH4OAC pH 4
(3mL), and absolute EtOH (100 μL), 1 (42 μL, 66 nmol) in
water was added and heated at 95 °C for 10min. The reac-
tion was cooled to room temperature (RT), and water
(TraceSELECT) was added. The solution was then passed
through a preconditioned C-18 SPE cartridge. The cart-
ridge was washed with water (10mL), and the product
([44Sc]3) was eluted with 400 μL EtOH. Prior to in vivo
evaluation, the eluate was heated until the EtOH content
was reduced to < 50 μL and saline (2.4mL) was added:
radiochemical yield (RCY), non-decay corrected (ndc) 85–
95%; radiochemical purity (RCP) > 99%; apparent molar ac-
tivity (Am) end of synthesis (EOS) 1GBq/μmol; HPLC Rt =
5.6min radio-TLC (0.1M citrate buffer, pH = 4) ([44Sc]3)
Rf = 0; (free
44Sc) Rf = 0.7–0.8. An aliquot was added to 2
(10 μg, 0.02 μmol) in saline (10 μL). After 5min, samples
were analysed using RP radio-TLC, RP radio-TLC (50%
MeCN/H2O) Rf ([
44Sc]3) = 0.9; Rf ([
44Sc]4) = 0.0.
Solution stability of [44Sc]3
Solutions of [44Sc]3 were prepared in saline (n = 3) and
HSA (n = 3) and incubated at 37 °C. Aliquots (n = 3) were
taken at 0.5, 1, 2, 4, and 24 h and analysed using RP
radio-TLC.
Animal studies
All animal experiments were approved by the ethical com-
mittee of the state of Rhineland Palatinate (according to §8
Abs. 1 Tierschutzgesetz, Landesuntersuchungsamt) and
performed in accordance with relevant federal laws and in-
stitutional guidelines. Male Wistar rats (age 5–6weeks,
mean weight 158 g) were obtained from Janvier and housed
in the central animal facility of the Johannes-Gutenberg-
University Medical Center, Mainz, Germany, under specific
pathogen-free conditions according to current federal, state,
and institutional guidelines with free access to water and
Fig. 1 Schematic of the bone-pretargeting strategy. Aln-TCO (2) is injected into healthy rats via the tail vein. After 1 h, the radiolabelled tetrazine
is injected. PET imaging occurs 4 h after injecting the radiolabelled tracer
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food. PET imaging was conducted using a Focus 120 (Sie-
mens) scanner.
Proof-of-concept PET with [44Sc]3
Rats (168–196 g) were positioned head first supine and
were anaesthetized with 2–2.5% isoflurane vaporized in
100% O2. Compound 2 (3mg/kg) in saline (168 μL) (n = 1)
or saline (196 μL) (n = 1) was administered via a peripheral
venous catheter inserted into a tail vein. After 1 h, [44Sc]3
(12MBq, 13–15 μg, 11–12 nmol) in saline was adminis-
tered and a 60-min dynamic PET scan was started
simultaneously. After the emission scan, a 30-min 57Co
transmission scan was performed. List mode data was
rebinned into framed sinograms and subsequently recon-
structed using Osem 2D (ramp filter, cut-off = 0.5) into 95
slices of 0.80mm thickness (pixel size 0.87 × 0.87mm2) and
a matrix of 128 × 128 pixels. Corrections were applied for
dead time, randoms, attenuation, and scatter. Regions of
interest were drawn in three different areas of the left and
right shoulders, and the muscle as background. Time-activ-
ity curves (TACs) were obtained using image-derived up-
take values, calculated as percent injected dose per millilitre
(% ID/mL).
Ex vivo biodistribution with [44Sc]3
In a similar fashion, rats (165–196 g) were positioned
head first supine and were anaesthetized with 2–2.5%
isoflurane vaporized in 100% O2. Compound 1 (3 mg/
kg) in saline (165–186 μL) (n = 4) or saline (169–196 μL)
(n = 2) was administered via a peripheral venous catheter
inserted into a tail vein. After 1 h, [44Sc]3 (9–12MBq,
12–20 μg, 9–15 nmol) in saline was administered. Rats
were sacrificed 4 h p.i. by an overdose of isoflurane, and
various tissues and organs were harvested and weighed.
Sample radioactivity was measured using a gamma
counter (Wizard2 2470, PerkinElmer), and the % ID/g
values were calculated. Biodistribution data was analysed
and plotted using GraphPad Prism (version 7).
Results
Radiolabelling and in vitro stability
A brief optimization of the RCY was performed for
[44Sc]3. Initially, the radiolabelling (Scheme 1) was per-
formed by heating a solution of 1 (39mmol) and
[44Sc]ScCl3 at 95 °C for 20min, followed by cooling to
room temperature and SPE purification. This resulted in
RCYs of only 25–28% (ndc). The reaction was analysed at
5, 10, and 20min reaction times, and it was observed that
longer reaction time resulted in the formation of uniden-
tifed side products, present as additional peaks in HPLC
chromatograms. A reaction time of 10min was then
chosen to reduce the side products and increased the
RCY. The ligand concentration was also increased to 66
nmol to provide a suitable TCO:Tz ratio for in vivo ana-
lysis. With these conditions in place, the radiosynthesis of
[44Sc]3 was accomplished in high RCYs (85–95% ndc) and
RCPs (> 99%), with an apparent Am of 1MBq/nmol
(EOS). Compound [44Sc]3 was stable for at least 24 h at
37 °C in saline and HSA (Additional file 1: Figure S2B).
Proof-of-concept evaluation with PET
Preclinical PET imaging of [44Sc]3 in healthy Wistar rats
pre-treated with 2 or saline is summarized in Fig. 2. The
total in vivo TCO:Tz ratio was 118:1 based on the amounts
of 2 and [44Sc]3 + 1 administered (Additional file 1: Table
S1). Small animal PET revealed radioactivity uptake in the
shoulders, elbows, wrists, and spinal cord when 2 was ad-
ministered 1 h prior to [44Sc]3 (Fig. 2a). This uptake was
not observed when 2 was not administered (Fig. 2b). Accu-
mulation of [44Sc]3 in the shoulders occurred rapidly and
was maintained throughout the duration of image acquisi-
tion (60min) (Fig. 2c). Radioactivity in these areas did not
rise above background when 2 was not administered.
Ex vivo biodistribution
The bone uptake was confirmed with an ex vivo biodis-
tribution study performed 4 h p.i. (Fig. 3). For the rats
Scheme 1 Radiosynthesis of [44Sc]3. The DOTA-functionalized Tz (1) was added to a solution of 44ScCl3 in ammonium acetate (pH 4) and ethanol.
The solution was heated to 95 °C for 10 min. After cooling to room temperature, the solution was loaded on to an SPE column, flushed with
water, and the pure product eluted with ethanol. [44Sc]3 was obtained in 85–95% RCY and > 99% RCP.
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pre-treated with 2, the total ratio of TCO:Tz administered
was between 114:1 and 134:1 (Additional file 1: Table S1).
The uptake in the femur and humerus was 0.9 ± 0.3%ID/g
in both areas. Radioactivity in the kidneys was 0.7 ± 0.2%
ID/g, while in all other organs and tissues it was below
0.1% ID/g (Fig. 3a). The clearance of [44Sc]3 from
non-targeted tissues resulted in high bone-to-soft tissue ra-
tios (Fig. 3b). High bone-to-blood (19.8 ± 0.4 femur, 18.9 ±
0.4 humerus) and bone-to-muscle (111.3 ± 0.4 femur, 106.0
± 0.5 humerus) ratios were observed (Fig. 3b). When 2 was
not administered, the only organs displaying substantial
radioactivity were the kidneys (0.8 ± 0.2%ID/g) (Fig. 3a).
Fig. 2 PET analysis of [44Sc]3 in Wistar rats. a Maximum intensity projection (MIP) of rat administered with 2 1 h prior to administration of 12 MBq
of [44Sc]3, 4 h p.i of radioactivity; sh shoulder, el elbow, wr wrist. b MIP of rat administered with saline 1 h prior to administration of 12 MBq of
[44Sc]3, 4 h p.i. of radioactivity. c TAC of radioactivity uptake in the muscle (background grey circles), left shoulder (red triangles), and right
shoulder (burgundy triangles) of rat pre-treated with 2 1 h prior to administering [44Sc]3. d TAC of radioactivity uptake in the muscle (background
grey circles) and left shoulder (red triangles) and right shoulder (burgundy triangles) of rat pre-treated with saline 1 h prior to administering
[44Sc]3. Three different ROIs were drawn for each shoulder to calculate the uptake value for the region
Fig. 3 Uptake values of [44Sc]3 in Wistar rats. a Ex vivo biodistribution 4 h p.i. of rats pre-treated with 2 or saline 1 h prior to administering 9–12
MBq of [44Sc]3. b Select bone soft tissue ratio of [44Sc]3 in rats pre-treated with 1 or saline
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Discussion
A DOTA-functionalized tetrazine (1) has been success-
fully labelled with the PET radionuclide, scandium-44, in
high RCY (85–95%) and RCP (> 99%) to produce [44Sc]3.
The Sc3+ ion is located within the DOTA cavity in a highly
unsymmetric manner. The coordination environment
around the Sc3+ ion can be both square-antiprismatic and
twisted anti-prismic, thus resulting in isomers [32]. In the
radiochromatogram for [44Sc]3, two peaks are present,
representing possible isomers formed in solution (Add-
itional file 1: Figure S1). Radio-TLC analysis revealed a
change in Rf value for all radioactive species when 2 was
added (Additional file 1: Figure S2). This indicates that all
radioactive species were reactive towards the TCO, sug-
gesting that the radioactive peaks in the chromatogram
represented isomeric tetrazine species. In a proof-of-con-
cept study, [44Sc]3 was evaluated using dynamic PET im-
aging concurrently to the ex vivo biodistribution. This
allowed real-time monitoring of the shoulder accumula-
tion and clearance from the background tissues. The TAC
(Fig. 2c) revealed that the radioactivity accumulation in
the shoulder occurred early (ca. 7–9min) and remained
fairly constant over 3.5 h. This gives an indication of the
speed of the IEDDA reaction as well as the radiochemical
and chemical stability of the dihydropyrole product
([44Sc]4). Although 2 is a small molecule and should ex-
hibit fast clearance, alendronate has been reported to bind
to rat serum proteins [33, 34]. This leaves a slight chance
that residual 2 may remain in the blood circulation and be
available for an in vivo reaction with [44Sc]3. Since bispho-
sphonates are internalized by osteoclasts overtime, a lon-
ger pretargeting interval would not be ideal when [44Sc]3
is used as the secondary agent, since it does not penetrate
cell membranes. For instance, pretargeted studies using 1
in mice have shown a reduction in bone uptake when
a longer pretargeting interval (> 12 h) was used [24].
The half-life of 44Sc was beneficial so that any [44Sc]4
formed from the residual 2 would clear from the
background tissues (blood and muscle) prior to image
acquisition. (Fig. 3b).
The utility of 2 in pretargeted studies has been previ-
ously studied as a primary agent to evaluate novel radi-
olabelled tetrazines for in vivo IEDDA reactions [21, 22,
35]. It is an attractive system in that it does not require
a disease model. This is advantageous for evaluating
novel tetrazines in higher order species where it would
be impossible or unethical to induce a diseased state. In
the initial studies, mice were pre-treated with relativity
high doses of 2 (20 mg/kg) prior to administering the
radiolabelled tetrazine [21, 22, 35]. Although high bone
uptake was observed (5–20% ID/g), high radioactivity in
the kidneys was also observed (8–13% ID/g). Interest-
ingly, it has been reported that the amount of renal ex-
cretion for alendronate increases with concentration in a
dose-dependent manner [36]. Although 2 is a modified
variant of alendronic acid, all bisphosphonates have the
potential to cause renal failure at high concentrations
[37]. For example, the bisphosphonates ibandronate and
zoledronate can result in renal decline in Wistar rats
when doses greater than 1 mg/kg or 3mg/kg (respect-
ively) are used [37]. Therefore, we opted to decrease the
dose of 2 to 3 mg/kg for the current study.
An additional advantage of 2 is that the amount of TCO
administered can be easily modified by changing the dose.
It has been shown that the number of pretargeted TCO
moieties can influence the uptake of the secondary agent
in pretargeted studies [35–37]. This is an important factor
to consider for clinical translation of the IEDDA reaction
as increasing the primary agent can lead to toxicity. We
have shown that by lowering the dose of 2, yet maintain-
ing a high ratio of the TCO:Tz administered, pretargeted
imaging was possible in a larger rodent model.
Conclusions
Radiolabelling of a DOTA-functionalized tetrazine with
generator-produced scandium-44 was optimized and im-
plemented. The labelled tracer ([44Sc]3) exhibited high
in vitro stability and was subsequently used for pretar-
geted imaging in rats via the IEDDA reaction. A
TCO-modified bisphosphonate, alendronate, was used as
the primary agent, and bone imaging was successful
using [44Sc]3. The half-life of scandium-44 was suitable
to obtain good clearance from non-targeted tissues giv-
ing rise to high T:NT ratios and excellent image quality.
Thus far, all of the tetrazines radiolabelled with typical
therapeutic nuclides (i.e., α or β− emitters) found in the
literature contain a DOTA-metal complex (for a review,
see [6]). Given the stability of Sc-DOTA complexes, the
convenient 44Sc-half-life, and the high-quality 44Sc-PET
images, scandium-44 is an attractive radionuclide to de-
velop companion diagnostics for these agents. Further-
more, we were able to demonstrate that pretargeted
imaging via IEDDA can be performed in rodents larger
than the typical mouse models previously used.
Additional files
Additional file 1: Figure S1. HPLC radiochromatogram chromatogram
of [44Sc]3 (Rt = 5.7 min). Figure S2. In vitro stability of [
44Sc]3. (A) radio-
TLC analysis of [44Sc]3 with 2 (lane 2) and without 2 (lane 1) following
radiosynthesis. (B) Percent intact over time after incubation in saline (red
circles) and human serum albumin (blue squares) for 0.5–24 h at 37 °C.
Table S1. Summary of the uptake for [44Sc]3 in Wistar rats. Table S2.
Summary of bone uptake values (4 h p.i.) and TCO:Tz ratios in individual
rats. (DOC 275 kb)
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